Member Info for KingHomerJ

In the clinical research industry, especially for a high-priority trial like ILiAD’s, a definitive contract is typically signed within 30 to 90 days of funding being secured, though specific factors can accelerate this to just a few weeks.

Typical Timelines for Clinical Contracts

Negotiation Speed: The median time for final contract negotiations is approximately 39 days, with full execution (all signatures) typically taking around 91 days.

The "Fast Track" Effect: For existing partners with a Letter of Intent (LOI) already in place—like hVIVO and ILiAD—the process is significantly faster because the major terms and costs have often been pre-negotiated.

UK-Specific Efficiency: In the UK, programs like the National Contract Value Review (NCVR) have reduced site contract negotiation times to an average of 29 days

Interestingly Hvivo have advertised the following roles on LinkedIn over the past 1/2 weeks

Clinical Support Specialist (12 month FTC)

Patient Enrolment Coordinator

Client Research Nurse (12 Month FTC)

The 12 Month FTC would be in line with the timelines of the Phase 3 study.....

The MHRA Innovation Passport, granted to ILiAD Biotechnologies on 4 December 2024, serves as a powerful catalyst for effectively de-risking the clinical timeline. By securing this elite status, the company has gained a "front-of-the-line" advantage that cuts through traditional regulatory bottlenecks and provides direct access to the UK’s advanced trial infrastructure. Critically, this regulatory head start is set to dramatically speed up the launch of the Phase 3 trial following the successful Series B funding round in February 2026.

Ready-to-Launch Protocols: ILiAD spent 2024 and 2025 finalising clinical trial protocols with global regulators like the FDA. Having these designs already "locked in" means the February 2026 funding can be immediately deployed toward execution rather than planning.

Reduced Operational Lead Time: Because the partnership with hVIVO was established via a Letter of Intent in early 2025, preliminary groundwork—such as site selection and initial logistics—is likely already handled. This allows the trial to bypass the typical 6-12 month "start-up" phase usually required for a study of this scale.

Predictable Enrollment Window: By utilizing a human challenge model that was validated in 2024-2025, ILiAD avoids the primary risk of Phase 3 trials: waiting for a natural disease outbreak. If the model and sites are "shovel-ready," the first patient dosing could occur as early as the first window of available facility space at hVIVO's Canary Wharf site.

As ever just needs to do another 20% 30% 40% and the masses will turn up as per…

Docs very confident……he’s put his money where his mouth is…..

Company gave premium options to employees 2 months ago

Let’s see if PYC does its weekly Friday Run ???

I mean frankly who cares what anyone thinks or says….

We make money…

We lose money…

It’s individuals choices regardless…..

It’s just unfortunate the way of the world is that 99% of people want people to fail vs the 1% that might actually be happy for you….

Ah well onwards on upwards regardless….life is a very simple thing…..

Wake up - Be Healthy - Be happy….

Simple really

GLA

Tickled me that (GET IT) lol

Not sure anyone has abandoned anyone. People just focus on themselves and hopefully make money.....maybe you should try it...

I mean INKOWNUFFIN mention Ken......Doc called Empire metals back in the day in the pennies....what was it like august 80p ? Yes the raised cash but shareholders till made significant life changing gains

DoseMe

DoseMe is a US based leading provider of model-informed precision dosing (MIPD) software, providing clinicians worldwide 'easy-to-use', decision-support tools to guide personalized dosing. In July 2024, DoseMe announced a major update of its DoseMeRx platform, creating a new user experience with added functionality. The platform is used by clinicians and practitioners worldwide, supporting dosing decisions for the treatment of a wide variety of diseases. As the largest Bayesian dosing platform in the US, with deployment across Europe, UK and further afield, the DoseMeRx platform provides Physiomics an effective route to initially deploy, but then eventually commercialise their Personalised Dosing Software. Furthermore, due to complimentary capabilities across the DoseMe and Physiomics businesses, both parties have identified the opportunities to collaborate on the development of new dosing software tools beyond GCSF and docetaxel.

The partnership builds on each party's core strengths, combing Physiomics' oncology and modelling expertise with DoseMe's experience in delivering dosing tools at scale, within clinical workflows.

Expansion of collaboration

Physiomics and DoseMe have recently signed non-binding Heads of Terms with the intention of expanding their partnership beyond the Company's current personalised dosing software. This agreement defines terms across four areas of collaboration:

· development and commercialisation of novel dosing software tools originating from Physiomics;

· development and commercialisation of novel dosing software tools originating from DoseMe or its clients;

· provision of consultancy services by the Company to DoseMe; and

· co-development of clinical trial dosing software in support of biopharmaceutical clients.

Opening stating he is buying on open market and has orders in.....

If he is indeed increasing his stake then id expect this to go on another run......

Physiomics PLC has formalized a data-sharing agreement with a top US university, a move that signals both scientific validation and accelerated growth potential. Partnering with such a prestigious institution serves as a strong endorsement of Physiomics’ computational biology platform, confirming that its technology meets the highest academic and research standards.

Beyond validation, the collaboration will dramatically increase the speed at which Physiomics can generate actionable insights. In an industry where speed is critical, this could shorten drug development timelines and improve operational efficiency, giving the company a clear competitive edge.

For investors, this partnership is more than symbolic. The combination of external validation and accelerated research capability positions Physiomics for rapid advancement in its pipeline, creating a tangible catalyst for a significant uptick in share price. As the market increasingly recognizes the credibility and potential of its platform, Physiomics is poised for both accelerated growth and heightened investor confidence

Physiomics plc is a uniquely positioned UK-listed biotech modelling and data-science company that is demonstrating accelerating commercial traction and diversifying revenue streams. Its latest interim results show strong pipeline execution with broadening contract wins and the launch of a Biostatistics service line, while moving steadily towards profitability with revenues growing ~46% year-on-year and losses shrinking.

The company is unlocking scalable value beyond traditional fee-for-service: its Virtual Tumour™ platform is gaining adoption for oncology drug modelling and dosing optimisation, and its personalised dosing software is now live on the DoseMeRx platform via a strategic US data-sharing and implementation agreement — positioning it to capture paid software revenues in addition to consulting.

Strategic initiatives, including a US university data-sharing agreement, validate its clinical relevance, while comparable companies trade at 30x current revenues. Given its accelerating commerciality and near-term profitability, the share price could realistically exceed 5p as market awareness grows.

And maybe a JOINT DEVELOPMENT agreement......

Many different ways to skin a cat as they say....

But what happens if they came to an agreement about licensing IP income.... Like VT Tech....Dosing Tool???

In other words...Dosemerx / Beyond Blood? With up front payments......

OH....Non Dilutive Revenue Streams......

1. Access to large, real-world clinical data

The dataset represents a substantial cohort of cancer patients undergoing treatment, which can be crucial for calibrating and validating Physiomics’ personalised dosing software — especially where clinical trial recruitment may be slower or limited in size.

2. Supplements internal clinical trial data

Physiomics is running its own observational study in Blackpool (linked to its personal dosing software initiative), but these trials are relatively small and still accumulating data. The university dataset provides additional, diverse patient information that can improve the robustness and generalisability of the software models.

3. Accelerating software development and validation

Access to external, high-quality patient data can significantly shorten the time needed to refine predictive models — especially for chemotherapy dosing and other parameters of personalised care — compared with relying solely on internal trial data.

4. Potential commercial and scientific credibility boost

Such partnerships — especially if with a reputable U.S. academic centre — can add credibility to Physiomics’ algorithms and data science approaches, which in turn supports future regulatory discussions, partnerships, and commercial uptake

Porky…..

I agreed wit everything you said on VAL for 3/4 years

However right now you are wrong….

I know it …

You know it …

I’ll leave it at that.

GL mate x

Think about what ya saying…..man f me lol

Read The RNS

“In July 2025, the Company announced the integration of its Personalised Dosing Software into the DoseMeRx platform and its expanded partnership with DoseMe Inc to advance new dosing solutions. As the largest Bayesian dosing platform in the US, also operating in Europe, the UK, and globally, the DoseMeRx platform is widely used by clinicians for dosing decisions across various diseases. The integration of Physiomics' Dosing Software onto the platform allows clinicians and healthcare providers access for research only purposes, allowing the Company to collate usability data to support model refinement. As calibration and validation are completed, updates based on user feedback will be deployed, paving the way for a commercial launch and paid for features.”

……its potential…..

Precision Dosing Tool – Multi-Million Revenue Potential

Physiomics’ precision dosing technology, developed in partnership with Beyond Blood Diagnostics, NHS Blackpool and DoseMeRx, represents one of the company’s most significant long-term value drivers.

Unlike traditional consultancy revenue, this is a scalable, recurring, software-driven product with global distribution through DoseMeRx, which is already deployed across hospitals and healthcare systems worldwide.

Once fully validated and commercialised, the dosing tool can be licensed per hospital, per department, or per clinician, creating a high-margin, repeat-revenue model rather than one-off service fees.

Comparable Example

A close comparator is DoseMeRx itself and other clinical decision-support platforms such as InsightRX (precision dosing software used by hospitals for drug optimisation). These platforms operate on subscription models that can generate multi-million annual revenues through hospital licensing and per-patient usage fees.

With even modest adoption — for example:

• 500 hospitals globally

• at £10,000 per year per site

This would already represent £5 million per year in recurring revenue.

At larger scale, this figure can reasonably rise into the tens of millions annually, before accounting for expansion into additional drugs and indications.

Strategic Value

Because this product sits directly inside a global platform (DoseMeRx), Physiomics does not need to build a global sales force to scale — the route to market is already in place. This dramatically lowers commercial risk and increases the likelihood of rapid adoption.

This single asset alone has the potential to transform Physiomics from a niche consultancy into a high-margin healthcare software company, justifying a valuation many times higher than its current market capitalisation

GlobalData